Galderma to Acquire ZO Skin Health for $1.5B, Bolstering…

Event summary

Galderma agrees to acquire ZO Skin Health for $1.5B in an all-cash deal, expected to close in Q4 2026 or early 2027.
ZO Skin Health recorded $330M in net sales over the last 12 months as of June 2026.
The acquisition aims to strengthen Galderma's physician-dispensed skincare offering, complementing its existing brands like Cetaphil and Alastin.
Galderma plans to increase commercial investment in ZO Skin Health post-acquisition to drive growth.

The big picture

Galderma's acquisition of ZO Skin Health underscores the company's commitment to strengthening its dermatology portfolio, particularly in the high-growth medical-grade skincare segment. The deal aligns with broader industry trends of consolidation and strategic investments in clinically-backed skincare brands. With an enterprise value of $1.5B, the acquisition is significant in scale and underscores Galderma's focus on expanding its offerings for dermatologists and aesthetic professionals.

What we're watching

Integration Strategy: How Galderma will integrate ZO Skin Health's protocol-based approach with its existing portfolio, particularly Alastin's peptide-based offerings.
Growth Trajectory: Whether the increased commercial investment will reignite ZO Skin Health's growth as anticipated by Galderma.
Market Positioning: The pace at which Galderma can solidify its position as a leader in the fast-growing medical-grade skincare segment.